Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. 2010

Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
Cancer Pharmacology and Therapeutics, St George Hospital Cancer Care, and Department of Surgery, St George Clinical School, University of New South Wales, Sydney, Australia.

OBJECTIVE Albendazole is a potential anticancer agent that is currently under development for the treatment of cancer. We carried out a dose-finding phase I study of oral albendazole in patients with advanced malignancies. METHODS Thirty-six patients with refractory solid tumors were enrolled. Albendazole was given orally on a day 1-14 of a 3 weekly cycle, starting at 400 mg BD with dose escalation until 1,200 mg BD. Serial blood samples were collected up to 96 h and also on day 8 of cycles 1 and 4. RESULTS The maximum tolerated dose was 2,400 mg per day (1,200 BD). Myelosuppression was the main dose limiting toxicity. Fatigue and mild gastrointestinal upset were the other major adverse effects. 4 out of 24 assessable patients (16%) had a tumor marker response with a fall of at least 50% from baseline values and another patient had a prolonged period of stable marker response. A decline in plasma vascular endothelial growth factor levels was observed. CONCLUSIONS Albendazole was well tolerated on the schedule tested in this trial. The results of this study suggest that the recommended dose for further study is 1,200 mg twice daily for 14 days in a 21-day cycle.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010146 Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. Suffering, Physical,Ache,Pain, Burning,Pain, Crushing,Pain, Migratory,Pain, Radiating,Pain, Splitting,Aches,Burning Pain,Burning Pains,Crushing Pain,Crushing Pains,Migratory Pain,Migratory Pains,Pains, Burning,Pains, Crushing,Pains, Migratory,Pains, Radiating,Pains, Splitting,Physical Suffering,Physical Sufferings,Radiating Pain,Radiating Pains,Splitting Pain,Splitting Pains,Sufferings, Physical
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005221 Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli. Lassitude

Related Publications

Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
February 2009, Clinical cancer research : an official journal of the American Association for Cancer Research,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
October 2015, Clinical cancer research : an official journal of the American Association for Cancer Research,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
December 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
March 2018, British journal of cancer,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
February 2020, Investigational new drugs,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
May 2010, Annals of oncology : official journal of the European Society for Medical Oncology,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
March 2021, Contemporary clinical trials communications,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
December 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
January 2000, The hematology journal : the official journal of the European Haematology Association,
Mohammad H Pourgholami, and Michael Szwajcer, and Melvin Chin, and Winston Liauw, and Jonathan Seef, and Peter Galettis, and David L Morris, and Matthew Links
February 2024, European journal of nuclear medicine and molecular imaging,
Copied contents to your clipboard!